Intraocular Lymphoma - 18 Studies Found
| Recruiting |
: Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma :
: 2012-02-27 :
|
| Active, not recruiting |
: Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma :
: Drug: Ibrutinib p.o. 560 mg once a day (four 140 mg capsules) for one year (12 cycles of 28 days) |
| Completed |
: A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma :
: 2005-09-14 : Drug: Intraventricular Rituximab Plus MTX Intraventricular |
| Suspended |
: Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma :
: |
| Withdrawn |
: Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma :
|
| Completed |
: Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma :
|
| Active, not recruiting |
: Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma :
: |
| Completed |
: Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma :
|
| Completed |
: 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas :
|
| Terminated |
: CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma :
: |